☆ 4.8 Article

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants

JOURNAL OF CLINICAL INVESTIGATION (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Qian Wang et al.

Summary: The BQ and XBB subvariants of SARS-CoV-2 Omicron, with additional spike mutations, are rapidly expanding and have altered antibody evasion properties. Neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by vaccinated individuals and infected persons' sera was significantly impaired, including those boosted with a WA1/BA.5 bivalent mRNA vaccine. The titers against BQ and XBB subvariants were much lower than observed before, indicating that these subvariants pose a serious threat to current COVID-19 vaccines and render all authorized antibodies inactive.

CELL (2023)

Add to Collection

Article Multidisciplinary Sciences

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Juan Manuel Carreno et al.

Summary: The Omicron variant of SARS-CoV-2, first identified in South Africa and Botswana in November 2021, has rapidly spread globally with high transmissibility. It has an unprecedented number of mutations in its spike gene, leading to immune escape and reduced vaccine efficacy. The neutralizing and binding activity against Omicron varies among individuals with different vaccination and infection histories.

NATURE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Laura A. VanBlargan et al.

Summary: The emergence of the B.1.1.529 Omicron variant raises concerns about the efficacy of antibody countermeasures. This study shows that some of the antibodies currently in clinical use may lose their ability to neutralize the Omicron variant.

NATURE MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

S. Momsen Reincke et al.

Summary: The Beta variant of concern (VOC) of SARS-CoV-2 shows resistance to neutralization by antibodies from COVID-19 patients and vaccinated individuals. Researchers have identified specific antibodies in serum from Beta-infected patients that are able to cross-react with the wild type virus. This finding provides insights into the antibody response to antigenic drift and has implications for the development of future vaccines and therapeutics.

SCIENCE (2022)

Add to Collection

Review Immunology

Protective neutralizing epitopes in SARS-CoV-2

Hejun Liu et al.

Summary: The COVID-19 pandemic has caused a global health crisis and economic burden. The SARS-CoV-2 virus, a new member of the coronavirus family, has infected hundreds of millions of people worldwide. Over the past 2 years, it has evolved to increase transmissibility and evade immunity from previous infection and vaccination. Immune responses from viral infection and vaccination have proven to be protective against variants, especially in terms of hospitalization or severe disease.

IMMUNOLOGICAL REVIEWS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Epitope-Analyzer: A structure-based webtool to analyze broadly neutralizing epitopes

Daniel Montiel-Garcia et al.

Summary: Antigenic epitopes on pathogens can be recognized by antibodies and cleared by the immune system. This study introduces a web-based tool, Epitope Analyzer (EA), that rapidly identifies conformational epitopes and paratope residues in antigen-antibody complex structures. By comparing equivalent epitope residues in similar antigen structures, the tool enables the analysis of broadly neutralizing epitopes. These findings can guide the development of effective treatments against multiple variants of viruses.

JOURNAL OF STRUCTURAL BIOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Structural diversity of the SARS-CoV-2 Omicron spike

Sophie M-C Gobeil et al.

Summary: The SARS-CoV-2 Omicron variant, aided by extensive spike protein mutation, has surpassed the previously dominant Delta variant. Cryo-EM structures of the Omicron and Delta spikes reveal the conformational impacts of mutations, with the Omicron spike showing a tightly packed RBD organization and increased flexibility at the fusion peptide site.

MOLECULAR CELL (2022)

Add to Collection

Article Multidisciplinary Sciences

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Jonathan L. Torres et al.

Summary: As the COVID-19 pandemic continues, highly potent monoclonal antibodies are needed to combat SARS-CoV-2 variants of concern. This study evaluates the efficacy of mAb J08 against these variants and investigates the binding details using cryo-EM and X-ray crystallography. The results demonstrate that mAb J08 has strong affinity against most variants and binds at a specific location on the receptor binding domain, away from the mutation sites. These findings further support the use of mAb J08 as a monoclonal therapy in ongoing clinical trials.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Microbiology

PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2

Viviana Simon et al.

Summary: This study provides a detailed description of the PARIS/SPARTA cohorts, harmonized assays, and analysis methods, as well as case definitions for SARS-CoV-2 infection and reinfection. Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of COVID-19.

MSPHERE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Meng Yuan et al.

Summary: Since the outbreak of COVID-19 pandemic, researchers from diverse biomedical and biological disciplines have collaborated to study the novel pandemic virus SARS-CoV-2. The focus has been on the antibody response to SARS-CoV-2, crucial for vaccine and therapeutic development. Most of the neutralizing antibodies for SARS-CoV-2 target the spike protein receptor binding domain (RBD).

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

UCSF ChimeraX: Structure visualization for researchers, educators, and developers

Eric F. Pettersen et al.

Summary: UCSF ChimeraX is a powerful visualization program with enhanced performance and graphics, offering new tools and analysis features, support for various areas like virtual reality, and improved ease of use, along with an app store for researchers to contribute new tools.

PROTEIN SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Raffael Nachbagauer et al.

Summary: New influenza virus vaccines based on chimeric hemagglutinin have been found to induce a broad, strong, durable and functional immune response targeting the conserved stalk of the hemagglutinin protein. This suggests that these chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.

NATURE MEDICINE (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike

Jenna J. Guthmiller et al.

Summary: The study reveals that individuals with more severe SARS-CoV-2 infection have a stronger overall antibody response to the spike and nucleocapsid proteins, and a larger memory B cell response against the spike. Additionally, these individuals develop antibodies that cross-react with other viral antigens, suggesting potential protection against reinfection.

MBIO (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Salim S. Abdool Karim et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Microbiology

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Fatima Amanat et al.

Summary: The spike protein of SARS-CoV-2 is identified as the prime target for vaccine development. Studies show that a soluble spike protein containing deleted polybasic cleavage site and K986P and V987P (PP) mutations completely protected mice from SARS-CoV-2 challenge, indicating the importance of antigen design for inducing protective immunity.

MBIO (2021)

Add to Collection

Article Microbiology

Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike

Siriruk Changrob et al.

Summary: The study identified 12 neutralizing monoclonal antibodies that neutralize various SARS-CoV-2 variants, indicating the need for different antibodies to combat different variants. This highlights the importance of inducing antibodies targeting multiple epitopes to tackle current and future emerging SARS-CoV-2 variants.

MBIO (2021)

Add to Collection

Article Multidisciplinary Sciences

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

Weina Sun et al.

Summary: The rapid development of COVID-19 vaccines has been crucial in mitigating the spread of SARS-CoV-2, but equitable allocation of vaccines is necessary to limit global impact and the emergence of variants. A Newcastle disease virus-based COVID-19 vaccine candidate has been developed, inducing protective immunity in various animal models.

NATURE COMMUNICATIONS (2021)

Add to Collection

Correction Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (vol 184, pg 2372, 2021)

Wilfredo F. Garcia-Beltran et al.

CELL (2021)

Add to Collection

Review Immunology

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants

Lok Bahadur Shrestha et al.

Summary: The emergence of SARS-CoV-2 variants has raised concerns globally, prompting research to find broadly neutralizing monoclonal antibodies to combat these variants. The discovery of these antibodies may help in the development of therapeutic antibodies and guide the discovery of second-generation vaccines.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

Haley L. Dugan et al.

Summary: Analyzing the evolution of memory B cells (MBCs) against SARS-CoV-2 is crucial for understanding antibody recall upon secondary exposure. Single-cell sequencing was used to profile SARS-CoV-2-reactive B cells in COVID-19 patients, revealing enrichment of SARS-CoV-2 spike-specific cells in the memory compartment and highly mutated variable genes in endemic HCoV-reactive antibody-secreting cells. Additionally, MBCs exhibited pronounced maturation to NP and ORF8 over time.

IMMUNITY (2021)

Add to Collection

Article Immunology

Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients

Qihong Yan et al.

Summary: Recent research has shown an increase in shared VH3-53-encoded antibodies targeting RBD in COVID-19 patients' antibody repertoires post-infection, with the identification of a highly shared VH3-53-J6 clonotype. These antibodies possess RBD binding and virus-neutralizing activities, recognizing the ACE2 binding site via the same molecular interface.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Article Immunology

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Aaron J. Schmitz et al.

Summary: The emergence of SARS-CoV-2 antigenic variants poses a public health threat, but analysis of monoclonal antibodies suggests that some antibodies can neutralize various variants. The study also found that an antibody called 2C08 has neutralizing effects against multiple variants and can reduce viral load and morbidity in animal models.

IMMUNITY (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Tyler N. Starr et al.

Summary: An ideal therapeutic anti-SARS-CoV-2 antibody should have resistance to viral escape, activity against diverse sarbecoviruses, and provide high protection through viral neutralization and effector functions. Studies have found a trade-off between in vitro neutralization potency and breadth of sarbecovirus binding in SARS-CoV-2 antibodies targeting the RBD, but identified some antibodies with exceptional sarbecovirus breadth and resistance to SARS-CoV-2 escape.

NATURE (2021)

Add to Collection

Letter Medicine, General & Internal

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Venkata-Viswanadh Edara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Meng Yuan et al.

Summary: Mutations in the RBS residues of new variant strains of the coronavirus can affect the binding and neutralizing effects of antibodies, but have little impact on antibodies targeting more conserved neutralizing sites.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Allison J. Greaney et al.

Summary: Vaccine-elicited antibodies have more focused neutralizing activity on the RBD of the SARS-CoV-2 spike protein, while infection-elicited antibodies have broader binding across epitopes; hence, single RBD mutations have less impact on neutralization by vaccine sera.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell Biology

First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes

Jenna J. Guthmiller et al.

Summary: Broadly neutralizing antibodies targeting conserved receptor-binding site (RBS) or lateral patch epitopes of hemagglutinin (HA) are recalled by first exposure to the 2009 pandemic H1N1 influenza virus. Monoclonal antibodies (mAbs) generated against these epitopes exhibit broad neutralizing activity against H1N1 viruses spanning 40 years of viral evolution, providing potent protection in vivo. Antibodies targeting the lateral patch are found to have near universal binding to H1 viruses, while RBS-binding antibodies commonly cross-react with H3N2 viruses and influenza B viruses.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Allison J. Greaney et al.

Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

Qi Zhang et al.

Summary: The study identifies potent neutralizing antibodies against SARS-CoV-2 with shared genetic features, termed as public antibodies. While one representative antibody demonstrates high protective efficacy in experiments, virus escape analysis reveals challenges faced by these public antibodies.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies

Claudia A. Jette et al.

Summary: This study characterizes two class 4 anti-RBD antibodies derived from COVID-19 donors that exhibit breadth and potent neutralization of zoonotic coronaviruses and SARS-CoV-2 variants. These antibodies work by occluding the ACE2 binding site and reducing sensitivity to variations in the protein structure.

CELL REPORTS (2021)

Add to Collection

Article Cell Biology

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Tyler N. Starr et al.

Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Current developments in Coot for macromolecular model building of Electron Cryo-microscopy and Crystallographic Data

Ana Casanal et al.

PROTEIN SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Meng Yuan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Controlling the SARS-CoV-2 spike glycoprotein conformation

Rory Henderson et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Philip J. M. Brouwer et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis of a shared antibody response to SARS-CoV-2

Meng Yuan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

Nicholas C. Wu et al.

CELL REPORTS (2020)

Add to Collection

Article Biochemical Research Methods

Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction

Ali Punjani et al.

NATURE METHODS (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Yixuan J. Hou et al.

SCIENCE (2020)

Add to Collection

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

Add to Collection

Article Microbiology

Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope

Goran Bajic et al.

CELL HOST & MICROBE (2019)

Add to Collection

Article Multidisciplinary Sciences

Outflanking immunodominance to target subdominant broadly neutralizing epitopes

Davide Angeletti et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Editorial Material Biochemical Research Methods

Deriving and refining atomic models in crystallography and cryo-EM: the latest Phenix tools to facilitate structure analysis

Bruno P. Klaholz

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Automatically Fixing Errors in Glycoprotein Structures with Rosetta

Brandon Frenz et al.

STRUCTURE (2019)

Add to Collection

Article Biology

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Jasenko Zivanov et al.

ELIFE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Gctf: Real-time CTF determination and correction

Kai Zhang

JOURNAL OF STRUCTURAL BIOLOGY (2016)

Add to Collection

Article Immunology

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

Jens Wrammert et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2011)

Add to Collection

Article Biochemical Research Methods

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Paul D. Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Appion: An integrated, database-driven pipeline to facilitate EM image processing

Gabriel C. Lander et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Add to Collection

Article Biochemistry & Molecular Biology

DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy

N. R. Voss et al.

JOURNAL OF STRUCTURAL BIOLOGY (2009)

Add to Collection

Article Chemistry, Multidisciplinary

Phaser crystallographic software

Airlie J. McCoy et al.

JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)

Add to Collection

Article Biochemistry & Molecular Biology

Automated molecular microscopy: The new Leginon system

C Suloway et al.

JOURNAL OF STRUCTURAL BIOLOGY (2005)

Add to Collection

Article Biochemical Research Methods

Coot:: model-building tools for molecular graphics

P Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)

Add to Collection

Article Chemistry, Multidisciplinary

UCSF chimera - A visualization system for exploratory research and analysis

EF Pettersen et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.